Combining sipuleucel-T and radium-223 improves progression-free survival among men with metastatic castration-resistant prostate cancer (mCRPC) who have bone predominant metastases, a randomized phase 2 study found.
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.
In a randomized, double-blind trial, short-term atorvastatin use before to radical prostatectomy did not improve postoperative erectile function compared with placebo.
In a study, radical prostatectomy for men with Gleason 8-10 prostate cancer and low PSA levels was associated with a lower death risk compared with external beam radiation therapy with or without brachytherapy.
Men on active surveillance for prostate cancer progress to treatment sooner if they undergo multiparametric MRI to identify clinically significant tumors.
Radical prostatectomy and ablation for salvage treatment of radiorecurrent prostate cancer do not differ significant with regard to cancer-specific and metastasis-free survival, a study found.
Radical prostatectomy (RP) for localized prostate cancer after a period of active surveillance offers overall and cancer-specific survival similar to that of men who undergo upfront RP.
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes.
In a study, just 12.1% of cases with focal positive surgical margins (PSM) experienced biochemical recurrence compared with 54.1% of those with extensive PSM.
In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.
